(原始内容存档于2020-10-21). Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase
of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.. Journal of Clinical Oncology
(页面存档备份,存于互联网档案馆) 本文含有此來源中屬於公有领域的内容。 FDA approves olutasidenib for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation. U.S. Food and